Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Enhanced hepatoprotection and bioavailability of silybin by coamorphous silybin-ursodeoxycholic acid

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: LIU, Dongchun (Shenyang Pharmaceutical University, department of Traditional Chinese Medicine, shenyang, China)
  • Co-author(s): Dongchun Liu: Faculty of Traditional Chinese Medicine, Shenyang Pharmaceutical University, Shenyang, China
    Xiafei Shi: Faculty of Traditional Chinese Medicine, Shenyang Pharmaceutical University, Shenyang, China
    Fang Wang: Faculty of functional food and wine, Shenyang Pharmaceutical University, Shenyang, China
    Huan Chen: Faculty of Traditional Chinese Medicine, Shenyang Pharmaceutical University, Shenyang, China
    Dong Wang: Faculty of Traditional Chinese Medicine, Shenyang Pharmaceutical University, Shenyang, China
    Yinghui Dai: Faculty of Traditional Chinese Medicine, Shenyang Pharmaceutical University, Shenyang, China
    Xing Tang: Faculty of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
  • Abstract:

    Backgrounds

    Silybin (SLB), an antihepatopathy flavonolignan derived from the herb milk thistle (Silybum marianum), is poorly soluble and exists in form of microcrystals,resulting in poor oral bioavailability. Ursodeoxycholic acid (UDCA), a kind of hydrophilic bile acid, is most widely used for the treatment of cholestatic hepatopathies. Combined..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses